Ost-müük Alimera Sciences, Inc. - ALIM CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | 0.23 | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.025457% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.003235% | ||||||||
Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Eelmine sulgemine* | 2.65 |
Avatud* | 2.6 |
Aastane muutus* | -54.14% |
Päeva ulatus* | 2.51 - 2.6 |
52 nädala ulatus | 1.30-7.92 |
Keskmine maht (10 päeva) | 3.73M |
Keskmine maht (3 kuud) | 12.89M |
Turukapitalisatsioon | 19.59M |
P/E suhtarv | -100.00K |
Ringluses olevad aktsiad | 7.40M |
Tulu | 55.78M |
EPS | -2.44 |
Dividendid (% kasumist) | N/A |
Beeta | 1.40 |
Järgmine tuluaruande kuupäev | Jul 25, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|---|---|---|---|---|---|
May 31, 2023 | 2.67 | 0.19 | 7.66% | 2.48 | 2.67 | 2.48 |
May 30, 2023 | 2.52 | 0.05 | 2.02% | 2.47 | 2.55 | 2.47 |
May 26, 2023 | 2.49 | 0.08 | 3.32% | 2.41 | 2.52 | 2.35 |
May 25, 2023 | 2.48 | -0.02 | -0.80% | 2.50 | 2.51 | 2.37 |
May 24, 2023 | 2.41 | 0.23 | 10.55% | 2.18 | 2.42 | 2.14 |
May 23, 2023 | 2.32 | -0.19 | -7.57% | 2.51 | 2.55 | 2.21 |
May 22, 2023 | 2.45 | 0.28 | 12.90% | 2.17 | 2.72 | 2.15 |
May 19, 2023 | 2.23 | 0.12 | 5.69% | 2.11 | 2.30 | 2.02 |
May 18, 2023 | 2.34 | -0.26 | -10.00% | 2.60 | 3.05 | 2.26 |
May 17, 2023 | 1.93 | 0.11 | 6.04% | 1.82 | 1.94 | 1.78 |
May 16, 2023 | 1.79 | 0.21 | 13.29% | 1.58 | 1.92 | 1.58 |
May 15, 2023 | 1.57 | -0.03 | -1.88% | 1.60 | 1.68 | 1.56 |
May 12, 2023 | 1.56 | -0.05 | -3.11% | 1.61 | 1.64 | 1.55 |
May 11, 2023 | 1.57 | 0.02 | 1.29% | 1.55 | 1.64 | 1.48 |
May 10, 2023 | 1.52 | -0.11 | -6.75% | 1.63 | 1.85 | 1.51 |
May 9, 2023 | 1.63 | -0.14 | -7.91% | 1.77 | 1.77 | 1.63 |
May 8, 2023 | 1.73 | -0.06 | -3.35% | 1.79 | 1.80 | 1.73 |
May 5, 2023 | 1.83 | -0.05 | -2.66% | 1.88 | 2.04 | 1.76 |
May 4, 2023 | 1.84 | 0.10 | 5.75% | 1.74 | 1.85 | 1.69 |
May 3, 2023 | 1.69 | 0.01 | 0.60% | 1.68 | 1.78 | 1.66 |
Alimera Sciences, Inc. Events
Kellaaeg (UTC) (UTC) | Riik | Sündmus |
---|---|---|
Wednesday, July 12, 2023 | ||
Kellaaeg (UTC) (UTC) 13:30 | Riik US
| Sündmus Alimera Sciences Inc Annual Shareholders Meeting Alimera Sciences Inc Annual Shareholders MeetingForecast -Previous - |
Tuesday, July 25, 2023 | ||
Kellaaeg (UTC) (UTC) 12:30 | Riik US
| Sündmus Q2 2023 Alimera Sciences Inc Earnings Release Q2 2023 Alimera Sciences Inc Earnings ReleaseForecast -Previous - |
Monday, November 13, 2023 | ||
Kellaaeg (UTC) (UTC) 13:30 | Riik US
| Sündmus Q3 2023 Alimera Sciences Inc Earnings Release Q3 2023 Alimera Sciences Inc Earnings ReleaseForecast -Previous - |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Kogutulu | 54.129 | 59.029 | 50.82 | 53.943 | 46.599 |
Tulu | 54.129 | 59.029 | 50.82 | 53.943 | 46.599 |
Kulud, Kokku | 7.977 | 7.03 | 6.941 | 6.626 | 4.308 |
Brutokasum | 46.152 | 51.999 | 43.879 | 47.317 | 42.291 |
Kogu tegevuskulu | 65.769 | 57.438 | 51.321 | 59.217 | 58.035 |
Müük/Üldine/admin kulud, kokku | 38.858 | 35.843 | 32.036 | 38.958 | 38.042 |
Uuringud ja arendus | 16.228 | 13.778 | 9.668 | 10.992 | 11.274 |
Depreciation / Amortization | 2.706 | 2.579 | 2.676 | 2.641 | 2.645 |
Ootamatud kulutused (tulu) | 0 | -1.792 | 0 | 1.766 | |
Tulud majandustegevusest | -11.64 | 1.591 | -0.501 | -5.274 | -11.436 |
Intressitulud (kulu), muud tulud, neto | -5.789 | -4.997 | -4.906 | -4.953 | -4.84 |
Netotulu enne makse | -18.079 | -3.934 | -5.407 | -10.227 | -16.276 |
Netotulu pärast makse | -18.107 | -4.372 | -5.339 | -10.443 | -16.382 |
Netotulu enne erikulusid | -18.107 | -4.372 | -5.339 | -10.443 | -16.382 |
Netotulu | -18.107 | -4.372 | -5.339 | -10.443 | -16.382 |
Arvestatav tulu, v a erikulud | -18.107 | -4.372 | -5.339 | -10.443 | 21.948 |
Arvestatav tulu, koos erikuludega | -18.107 | -4.372 | -5.339 | -10.443 | 21.948 |
Jaotamisele kuuluv netotulu | -18.107 | -4.372 | -5.339 | -10.443 | 21.948 |
Keskmine jaotamisele kuuluv aktsia kohta | 6.99685 | 6.59524 | 5.11766 | 4.7702 | 5.91587 |
Jaotatav EPS, v a erakorralised kulud | -2.58788 | -0.6629 | -1.04325 | -2.18921 | 3.71002 |
Jaotamisele kuuluv normaal-EPS | -2.58788 | -0.83951 | -1.04325 | -2.18921 | 3.90406 |
Other Operating Expenses, Total | |||||
Erakorralised kulud kokku | 0 | 0 | |||
Total Adjustments to Net Income | 0 | 38.33 | |||
Muud, neto | -0.65 | -0.528 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Kogutulu | 13.546 | 14.029 | 13.598 | 14.604 | 11.898 |
Tulu | 13.546 | 14.029 | 13.598 | 14.604 | 11.898 |
Kulud, Kokku | 2.028 | 2.125 | 2.006 | 2.166 | 1.68 |
Brutokasum | 11.518 | 11.904 | 11.592 | 12.438 | 10.218 |
Kogu tegevuskulu | 16.848 | 16.137 | 17.009 | 16.578 | 16.045 |
Müük/Üldine/admin kulud, kokku | 9.975 | 9.099 | 9.856 | 9.81 | 10.093 |
Uuringud ja arendus | 4.164 | 4.23 | 4.483 | 3.932 | 3.583 |
Depreciation / Amortization | 0.681 | 0.683 | 0.664 | 0.67 | 0.689 |
Tulud majandustegevusest | -3.302 | -2.108 | -3.411 | -1.974 | -4.147 |
Intressitulud (kulu), muud tulud, neto | -1.68 | -1.621 | -1.567 | -1.345 | -1.256 |
Netotulu enne makse | -4.968 | -3.781 | -5.245 | -3.098 | -5.955 |
Netotulu pärast makse | -4.968 | -3.78 | -5.257 | -3.115 | -5.955 |
Netotulu enne erikulusid | -4.968 | -3.78 | -5.257 | -3.115 | -5.955 |
Netotulu | -4.968 | -3.78 | -5.257 | -3.115 | -5.955 |
Arvestatav tulu, v a erikulud | -4.982 | -3.78 | -5.257 | -3.115 | -5.955 |
Arvestatav tulu, koos erikuludega | -4.982 | -3.78 | -5.257 | -3.115 | -5.955 |
Jaotamisele kuuluv netotulu | -4.982 | -3.78 | -5.257 | -3.115 | -5.955 |
Keskmine jaotamisele kuuluv aktsia kohta | 7.03223 | 7.00032 | 6.99658 | 6.99971 | 6.99074 |
Jaotatav EPS, v a erakorralised kulud | -0.70845 | -0.53998 | -0.75137 | -0.44502 | -0.85184 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Jaotamisele kuuluv normaal-EPS | -0.70845 | -0.53998 | -0.75137 | -0.44502 | -0.85184 |
Ootamatud kulutused (tulu) | 0 | 0 | 0 | ||
Muud, neto | 0.014 | -0.052 | -0.267 | 0.221 | -0.552 |
Total Adjustments to Net Income | -0.014 |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Käibevarad kokku | 29.413 | 42.16 | 34.906 | 32.745 | 34.848 |
Raha ja lühiajalised investeeringud | 5.274 | 16.51 | 11.208 | 9.426 | 13.043 |
Raha ja ekvivalendid | 5.274 | 16.51 | 11.208 | 9.426 | 13.043 |
Laekumata arved, neto | 19.612 | 19.128 | 17.2 | 19.331 | 17.259 |
Accounts Receivable - Trade, Net | 19.612 | 19.128 | 17.2 | 19.331 | 17.259 |
Total Inventory | 1.605 | 2.679 | 2.746 | 1.39 | 2.405 |
Prepaid Expenses | 2.892 | 3.809 | 3.718 | 2.565 | 2.109 |
Other Current Assets, Total | 0.03 | 0.034 | 0.034 | 0.033 | 0.032 |
Total Assets | 42.602 | 58.52 | 50.855 | 50.309 | 54.108 |
Property/Plant/Equipment, Total - Net | 3.92 | 4.493 | 2.358 | 2.047 | 1.355 |
Property/Plant/Equipment, Total - Gross | 7.981 | 7.923 | 6.305 | 5.858 | 4.967 |
Accumulated Depreciation, Total | -4.061 | -3.43 | -3.947 | -3.881 | -3.612 |
Intangibles, Net | 8.957 | 10.897 | 12.838 | 14.783 | 16.723 |
Other Long Term Assets, Total | 0.129 | 0.137 | 0.753 | 0.734 | 1.182 |
Total Current Liabilities | 39.732 | 12.592 | 12.348 | 12.048 | 10.234 |
Accounts Payable | 10.088 | 8.706 | 7.461 | 7.077 | 6.355 |
Accrued Expenses | 3.998 | 3.617 | 3.197 | 4.716 | 3.643 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 25.646 | 0.269 | 1.69 | 0.255 | 0.236 |
Other Current Liabilities, Total | |||||
Total Liabilities | 63.41 | 61.125 | 58.833 | 54.754 | 51.386 |
Total Long Term Debt | 18.683 | 43.08 | 42.922 | 38.752 | 38.178 |
Long Term Debt | 18.683 | 43.08 | 42.408 | 38.658 | 37.873 |
Capital Lease Obligations | 0.514 | 0.094 | 0.305 | ||
Other Liabilities, Total | 4.995 | 5.453 | 3.563 | 3.954 | 2.974 |
Total Equity | -20.808 | -2.605 | -7.978 | -4.445 | 2.722 |
Preferred Stock - Non Redeemable, Net | 19.227 | 19.227 | 19.227 | 30.344 | 30.344 |
Common Stock | 0.07 | 0.069 | 0.057 | 0.05 | 0.701 |
Additional Paid-In Capital | 378.238 | 377.229 | 365.83 | 350.117 | 346.108 |
Retained Earnings (Accumulated Deficit) | -415.388 | -397.281 | -392.539 | -383.863 | -373.42 |
Other Equity, Total | -2.955 | -1.849 | -0.553 | -1.093 | -1.011 |
Total Liabilities & Shareholders’ Equity | 42.602 | 58.52 | 50.855 | 50.309 | 54.108 |
Total Common Shares Outstanding | 6.99551 | 6.93515 | 5.71937 | 4.96595 | 4.67193 |
Total Preferred Shares Outstanding | 0.6 | 0.6 | 0.6 | 0.61015 | 0.61015 |
Long Term Investments | 0.183 | 0.833 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Käibevarad kokku | 35.675 | 29.413 | 29.76 | 33.073 | 34.753 |
Raha ja lühiajalised investeeringud | 13.086 | 5.274 | 5.514 | 7.859 | 9.946 |
Raha ja ekvivalendid | 13.086 | 5.274 | 5.514 | 7.859 | 9.946 |
Laekumata arved, neto | 18.433 | 19.612 | 19.142 | 20.319 | 18.776 |
Accounts Receivable - Trade, Net | 18.433 | 19.612 | 19.142 | 20.319 | 18.776 |
Total Inventory | 1.215 | 1.605 | 1.786 | 1.656 | 2.452 |
Prepaid Expenses | 2.91 | 2.892 | 3.29 | 3.208 | 3.546 |
Other Current Assets, Total | 0.031 | 0.03 | 0.028 | 0.031 | 0.033 |
Total Assets | 48.239 | 42.602 | 43.429 | 47.574 | 49.931 |
Property/Plant/Equipment, Total - Net | 3.757 | 3.92 | 3.87 | 3.938 | 4.343 |
Intangibles, Net | 8.479 | 8.957 | 9.446 | 9.935 | 10.419 |
Other Long Term Assets, Total | 0.131 | 0.129 | 0.118 | 0.126 | 0.134 |
Total Current Liabilities | 14.173 | 39.732 | 34.01 | 25.431 | 17.006 |
Accounts Payable | 9.669 | 10.088 | 8.706 | 7.614 | 6.604 |
Accrued Expenses | 4.241 | 3.998 | 3.661 | 3.316 | 3.046 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.263 | 25.646 | 21.643 | 14.501 | 7.356 |
Total Liabilities | 67.155 | 63.41 | 61.507 | 59.909 | 58.534 |
Total Long Term Debt | 44.312 | 18.683 | 22.492 | 29.297 | 36.245 |
Long Term Debt | 44.152 | 18.683 | 22.492 | 29.297 | 36.245 |
Capital Lease Obligations | 0.16 | ||||
Other Liabilities, Total | 8.67 | 4.995 | 5.005 | 5.181 | 5.283 |
Total Equity | -18.916 | -20.808 | -18.078 | -12.335 | -8.603 |
Preferred Stock - Non Redeemable, Net | 7.728 | 19.227 | 19.227 | 19.227 | 19.227 |
Common Stock | 0.074 | 0.07 | 0.07 | 0.07 | 0.07 |
Additional Paid-In Capital | 378.146 | 378.238 | 378.005 | 377.847 | 377.541 |
Retained Earnings (Accumulated Deficit) | -402.081 | -415.388 | -411.608 | -406.351 | -403.236 |
Other Equity, Total | -2.783 | -2.955 | -3.772 | -3.128 | -2.205 |
Total Liabilities & Shareholders’ Equity | 48.239 | 42.602 | 43.429 | 47.574 | 49.931 |
Total Common Shares Outstanding | 7.39159 | 6.99551 | 6.99802 | 6.99546 | 6.99265 |
Total Preferred Shares Outstanding | 0.012 | 0.6 | 0.6 | 0.6 | 0.6 |
Long Term Investments | 0.197 | 0.183 | 0.235 | 0.502 | 0.282 |
Other Current Liabilities, Total |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Netotulu/algväärtus | -18.107 | -4.372 | -5.339 | -10.443 | -16.382 |
Raha majandustegevusest | -9.975 | -3.224 | -2.193 | -4.152 | -11.553 |
Raha majandustegevusest | 2.706 | 2.579 | 2.676 | 2.641 | 2.645 |
Deferred Taxes | 0.116 | 0.61 | 0.031 | 0.454 | -0.653 |
Mittelikviidsed varad | 2.621 | -0.692 | 1.829 | 3.377 | 7.084 |
Cash Taxes Paid | 0.232 | 0.112 | 0.11 | 0.239 | 0.239 |
Makstud intressid | 4.489 | 4.302 | 4.556 | 4.419 | 3.571 |
Muutused tööjõus | 2.689 | -1.349 | -1.39 | -0.181 | -4.247 |
Tulu investeeringutelt | -0.255 | -0.621 | -0.62 | -0.174 | -0.175 |
Kapitalikulutused | -0.255 | -0.621 | -0.62 | -0.174 | -0.175 |
Rahavood investeeringutelt | -0.302 | 9.823 | 3.882 | 0.869 | 0.95 |
Rahavoogudesse investeerimine | -0.113 | 0 | -0.019 | -2.227 | -3.808 |
Aktsiate emiteerimine (tagasiost), neto | 0.1 | 10.044 | 0.049 | 0.902 | 0.085 |
Laenu väljastamine (kustutamine), neto | -0.289 | -0.221 | 3.852 | 2.194 | 4.673 |
Muutused valuutakursside kõikumisest | -0.708 | -0.676 | 0.714 | -0.159 | -0.248 |
Rahaline kogumuutus | -11.24 | 5.302 | 1.783 | -3.616 | -11.026 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -4.968 | -18.107 | -14.327 | -9.07 | -5.955 |
Cash From Operating Activities | -2.209 | -9.975 | -9.724 | -7.811 | -6.213 |
Cash From Operating Activities | 0.681 | 2.706 | 2.023 | 1.359 | 0.689 |
Non-Cash Items | 0.507 | 2.621 | 2.095 | 1.318 | 1.027 |
Cash Taxes Paid | 0 | 0.232 | 0.224 | 0.182 | 0.018 |
Cash Interest Paid | 1.354 | 4.489 | 3.253 | 2.145 | 1.061 |
Changes in Working Capital | 1.571 | 2.689 | 0.485 | -1.418 | -1.974 |
Cash From Investing Activities | -0.009 | -0.255 | -0.171 | -0.041 | -0.149 |
Capital Expenditures | -0.009 | -0.255 | -0.171 | -0.041 | -0.149 |
Cash From Financing Activities | 9.998 | -0.302 | -0.109 | -0.164 | -0.062 |
Financing Cash Flow Items | -3.123 | -0.113 | |||
Issuance (Retirement) of Debt, Net | 2.373 | -0.289 | -0.164 | -0.204 | -0.062 |
Foreign Exchange Effects | 0.033 | -0.708 | -0.998 | -0.638 | -0.141 |
Net Change in Cash | 7.813 | -11.24 | -11.002 | -8.654 | -6.565 |
Issuance (Retirement) of Stock, Net | 10.748 | 0.1 | 0.055 | 0.04 | |
Deferred Taxes | 0.116 |
Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
---|---|---|---|---|---|---|
Velan Capital Investment Management LP | Investment Advisor/Hedge Fund | 22.4131 | 1659654 | 1401901 | 2023-05-17 | MED |
Ocumension Therapeutics | Corporation | 15.4621 | 1144945 | 0 | 2023-04-24 | LOW |
Morgan Stanley & Co. LLC | Research Firm | 8.9243 | 660832 | 0 | 2023-03-31 | MED |
Caligan Partners, LP | Hedge Fund | 6.4657 | 478777 | 0 | 2023-05-17 | MED |
Eiswirth (Richard S Jr) | Individual Investor | 4.3555 | 322518 | 500 | 2023-04-24 | LOW |
HOOPP Investment Management | Pension Fund | 3.3762 | 250000 | 0 | 2023-03-31 | HIGH |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.0071 | 148624 | 0 | 2023-03-31 | LOW |
Ashman Philip | Individual Investor | 1.8004 | 133315 | 0 | 2023-04-24 | MED |
Holland (David R) | Individual Investor | 1.4704 | 108880 | 500 | 2023-04-24 | LOW |
Renaissance Technologies LLC | Hedge Fund | 1.3693 | 101394 | -1100 | 2023-03-31 | HIGH |
Skibsted (Russell L) | Individual Investor | 1.0196 | 75500 | 58000 | 2023-03-26 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5167 | 38262 | 0 | 2023-03-31 | LOW |
Jones (John Philip) | Individual Investor | 0.4347 | 32186 | 372 | 2022-10-31 | |
Millennium Management LLC | Hedge Fund | 0.3884 | 28762 | 16799 | 2023-03-31 | HIGH |
Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.2639 | 19542 | 0 | 2023-03-31 | MED |
Bridgeway Capital Management, LLC | Investment Advisor | 0.2471 | 18300 | 0 | 2023-03-31 | LOW |
Perritt Capital Management, Inc. | Investment Advisor | 0.2431 | 18000 | 0 | 2023-03-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.175 | 12962 | 438 | 2023-03-31 | LOW |
J.P. Morgan Securities LLC | Research Firm | 0.14 | 10364 | 9838 | 2023-03-31 | MED |
Snisarenko (John) | Individual Investor | 0.135 | 10000 | 0 | 2023-04-24 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group535K+
Kauplejad
87K+
Igakuiste aktiivsete klientide arv
$113M+
Igakuine investeerimise maht
$64M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Alimera Sciences, Inc. Company profile
Ettevõttest Alimera Sciences, Inc.
Alimera Sciences, Inc. on farmaatsiaettevõte. Ettevõte tegeleb retsepti alusel väljastatavate silmaravimite turustamise ja arendamisega. See keskendub silma tagakülge ehk võrkkesta mõjutavatele haigustele. Ettevõtte kaubanduslik toode ILUVIEN on intravitreaalne implantaat, mis ravib patsiente, manustades silma kuni 36 kuu jooksul pidevat mikrodoosi ravimiteta kortikosteroidi fluotsinoloonatsetoniidi (FAc). Ettevõte tegeleb diabeetilise makulaödeemi (DME) ravi arendamisega. DME on võrkkesta haigus, mis mõjutab diabeeti põdevaid inimesi ja võib põhjustada tõsist nägemise kaotust ja pimedaks jäämist. ILUVIENi saab kasutada ka tagumise silma tagumise segmendi (NIU-PS) retsidiivse mitteinfektsioosse uveiidi ägenemise vältimiseks. Ettevõte turustab ILUVIENi otse Ameerika Ühendriikides, Saksamaal, Ühendkuningriigis, Portugalis ja Iirimaal.
Industry: | Biopharmaceuticals |
Ste 290
6120 Windward Parkway
ALPHARETTA
GEORGIA 30005
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 535,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com